SharkNinja R&D increased by 12.9% to $98.88M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.9%, from $87.60M to $98.88M.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $62.35M | $62.35M | $62.35M | $62.35M | $85.32M | $85.32M | $85.32M | $85.32M | $87.60M | $98.88M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +36.9% | +0.0% | +0.0% | +0.0% | +2.7% | +12.9% |
| YoY Change | — | — | — | — | +36.9% | +36.9% | +36.9% | +36.9% | +2.7% | +12.9% |